Breaking News
Get 40% Off 0
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool. See stock ideas
Close

Pyxis Oncology Inc (PYXS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Pyxis Oncology's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.290 -0.050    -1.15%
13/05 - Closed. Currency in USD ( Disclaimer )
After Hours
4.400
+0.110
+2.564%
19:14:23 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 275,449
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.160 - 4.480
Pyxis Oncology 4.290 -0.050 -1.15%

Pyxis Oncology Inc Company Profile

 
Get an in-depth profile of Pyxis Oncology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

50

Equity Type

ORD

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Contact Information

Address 321 Harrison Avenue 11th Floor, Suite 1
Boston, 02118
United States
Phone 617 221 9059
Fax -

Top Executives

Name Age Since Title
Darren S. Cline 60 2021 Independent Director
Robert Baffi - - Member of Technical Advisory Board
Michael Sun - - Member of Technical Advisory Board
Thomas Civik 55 2021 Independent Director
Freda C. Lewis-Hall 69 2021 Independent Director
Jason J. Luke - - Member of Clinical & Translational Medicine Advisory Board
Virgil Bryan Lawlis - - Member of Technical Advisory Board
Anthony W. Tolcher - 2021 Member of Clinical & Translational Medicine Advisory Board
Christopher O’Donnell 54 2021 Member of Technical Advisory Board
Morris Rosenberg - - Chairperson of Technical Advisory Board
Jakob Dupont 59 2023 Independent Director
Rachel Wallach Humphrey 63 2022 Independent Director
Elliott M. Levy 66 2023 Member of Clinical & Translational Medicine Advisory Board
Patricia LoRusso - 2023 Member of Clinical & Translational Medicine Advisory Board
Giulio Draetta - 2023 Member of Clinical & Translational Medicine Advisory Board
Glenn A. Miller - 2023 Member of Clinical & Translational Medicine Advisory Board
Paul A. Bunn - 2023 Member of Clinical & Translational Medicine Advisory Board
Santhosh Palani 40 2024 Independent Director
Lara S. Sullivan - 2019 CEO, President & Director
John L. Flavin 53 2019 Independent Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PYXS Comments

Write your thoughts about Pyxis Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giuseppe Giannachi
Giuseppe Giannachi Feb 12, 2024 6:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news or ideas, after the recent PT raises? Cheers.
Mikael Ramfeldt
Mikael Ramfeldt Mar 31, 2023 12:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pelosi buying, pfizer buying and insiders buying. There must be something coming. this is only temporary drop cause it was so sharp up. I join owners team today.
Jacob Powers
Jacob Powers Mar 31, 2023 12:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do you feel this will have a good chanve of coming back?
Laurie Whipple
Laurie Whipple Mar 31, 2023 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Who ever called Pump and Dump was right
Mikael Ramfeldt
Mikael Ramfeldt Mar 31, 2023 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont think it is s pump and dump. climb was just too fast and sharp.
Jacob Powers
Jacob Powers Mar 31, 2023 10:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why is it tanking?!
Laurie Whipple
Laurie Whipple Mar 30, 2023 2:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought at 5 sold at 6.25
Most expensive Hobby
Most expensive Hobby Mar 28, 2023 1:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy and hold
Norman Byler
Norman Byler Mar 28, 2023 8:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nancy is buying! lol
Brayden Porter
Brayden Porter Mar 28, 2023 8:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yep
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email